34 |
TRITON - TIMI 38: The Future Role of Prasugrel (and Other New Anti-Platelet Agents) in PCI |
Roxana Mehran |
Jun. 23. 09 |
33 |
The Role of Triple Antiplatelet Therapy in Patients with High Risk |
Young-Hoon Jeong |
May. 13. 09 |
32 |
Tailoring Treatment to Risk in Antiplatelet Therapy |
Alexandra J. Lansky |
May. 13. 09 |
31 |
Updated Antiplatelet Therapy After PCI; Prasugrel, AZD6140..;The Future We Can Expect in Routine Practice? |
David Joel Cohen |
May. 13. 09 |
30 |
What Is the Optimal Duration of Dual Antiplatelet Therapy Following DES Treatment? |
David E. Kandzari |
May. 13. 09 |
29 |
Updated Data and Clinical Application of Triple Antiplatelet Therapy: The Answer to Patients with CYP 2C19 Polymorphism and High Post-Treatment Platelet Reactivity After Clopidogrel? |
Seung-Whan Lee |
May. 13. 09 |
28 |
Polymorphism in Metabolism of Clopidogrel and Its Clinical Implication and Management |
Alexandra J. Lansky |
May. 13. 09 |
27 |
Clopidogrel Response Variability and Platelet Function Testing: Should Routine Practice Be Changed in Interventional Cardiology? |
Matthew Price |
May. 13. 09 |
26 |
TAILORED CLOPIDOGREL LOADING DOSE ACCORDING TO PLATELET REACTIVITY MONITORING DECREASE EARLY STENT THROMBOSIS |
|
Jan. 07. 09 |
25 |
FATA: Tirofiban vs. Abciximab in Patients with AMI Undergoing Primary PCI |
Francesco Saia |
Dec. 09. 08 |